Oncology Institute, Inc. (TOI) Amortization of Deferred Charges (2021 - 2026)

Oncology Institute (TOI) has 6 years of Amortization of Deferred Charges data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Amortization of Deferred Charges fell 75.15% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 50.97% YoY) and the FY2025 annual result came in at $8.4 million, up 32.91% from the prior year.
• Amortization of Deferred Charges held at $1.2 million in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $4.9 million in Q1 2025 to a low of $892000.0 in Q3 2022.
• A 5-year average of $1.6 million and a median of $1.6 million in 2022 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges jumped 4855.56% — and 2026, when it tumbled 75.15%.
• Tracing TOI's Amortization of Deferred Charges over 5 years: stood at $1.6 million in 2022, then gained by 1.29% to $1.6 million in 2023, then rose by 1.4% to $1.6 million in 2024, then fell by 24.4% to $1.2 million in 2025, then grew by 0.5% to $1.2 million in 2026.
• The last three Amortization of Deferred Charges figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.